



JOINT MEETING 2024 ALDOSTERONE & MINERALOCORTICOID RECEPTOR

APRIL 19-20, 2024
FREIBURG, GERMANY

Keynote speakers

Morris J. Brown (UK)
Timothy A. McKinsey (USA)

Venue

University of Freiburg
Otto-Krayer-Haus
Albertstr. 25 | 79104 Freiburg
Germany

Registration and Abstract submission

by March 8, 2024

Organizers

A Lothar (Freiburg, GER)
J Bauersachs (Hannover, GER)

<http://meeting.admire-network.org>



supported by

universität freiburg



DFG Deutsche
Forschungsgemeinschaft

**Joint Meeting of the European Section of the Aldosterone Council (ESAC) and the
ADMIRE Network on Aldosterone & the Mineralocorticoid Receptor**

Freiburg, Germany, April 19-20, 2024

Scientific Program

Friday, 19.04.2024

Registration, get together & poster set-up **11:15 13:15**

Welcome (Achim Lothar) **13:15 13:30**

Aldosterone and MR in arterial hypertension (Chair: Frederic Jaisser) **13:30 14:45**

Ulrich Wenzel
(Hamburg, GER) Immunity in hypertension and hypertensive organ injury 25 + 5 min

Paul Neumann
(Berlin, GER) Monocyte polarization in patients with primary aldosteronism 10 + 5 min

May Fayad
(Paris, FR) Role of the mineralocorticoid receptor in the physiology of the adrenal cortex and the development of aldosterone producing adenomas 10 + 5 min

Ana Rita Leite
(Porto, POR) Blood Pressure Response To Mineralocorticoid Inhibitors According To Baseline Renin Levels 10 + 5 min

Morris Brown (London, UK)	Keynote lecture: Aldosterone in arterial hypertension: from genetics to therapeutic targeting (Chair: Christina Zennaro)	14:45 15:45
------------------------------	--	--------------------

Poster session with coffee (Chairs: Antoine Ouvrard-Pascaud, Tilmann Volk) **15:45 17:15**

Aldosterone and MR in cardio-renal-metabolic disorders (Chair: Johann Bauersachs) **17:15 18:30**

Lisa Cronin
(Ridgefield, USA) Aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease – a phase II clinical trial 25 + 5 min

Massimiliano Caprio
(Rome, ITA) Ketones effects on the RAAS: metabolic and cardiovascular implications 25 + 5 min

Manon Monmirel
(Rouen, FR) Mineralocorticoid receptor antagonism improves HFpEF in obese female mice and slows down its acceleration after a postmenoapusal transtion 10 + 5 min

Dinner reception **19:30 23:00**

Saturday, 20.04.2024

Nuclear receptor signaling: MR and beyond (Chair: Diego Alvarez de la Rosa) 09:00 10:30

Onno Meijer (Leiden, NED)	MR-GR crosstalk in the brain	25 + 5 min
Paloma Perez (Valencia, ESP)	MR-GR crosstalk in the skin	25 + 5 min
Fania Rahmadani (Munich, GER)	Hepatic Mineralocorticoid Receptor functions in crosstalk with the Glucocorticoid Receptor	10 + 5 min
Brian Harvey (Dublin, IRL)	Protein Kinase D3: a novel regulator of Aldosterone/MR activation of ENaC in CCD cells	10 + 5 min

Coffee break with posters 10:30 11:30

Timothy A. McKinsey (Denver, USA)	Keynote lecture: Epigenetic therapies for cardiac fibrosis (Chair: Achim Lothar)	11:30 12:30
--------------------------------------	--	--------------------

Cell type-specific roles of MR in disease (Chair: Say Viengchareun) 12:30 13:30

David Meral (Freiburg, GER)	Deciphering gene expression in reversible aldosterone-induced heart failure with preserved ejection fraction at single cell resolution	10 + 5 min
Leonardo von der Ohe (Berlin, GER)	Aldosterone-associated monocyte recruitment contributes to right ventricular dysfunction	10 + 5 min
Ernesto Martín-Nuñez (Pamplona, ESP)	Aldo/MR axis mediates calcific phenotypes in valve interstitial cells through chemerin in diabetic men with aortic stenosis	10 + 5 min
Sheearzed Boulkroun (Paris, FR)	MR inhibition in parietal epithelial cells prevents glomerular injury during focal segmental glomerulosclerosis and crescentic glomerulonephritis	10 + 5 min

Poster awards & farewell (Chairs: Johann Bauersachs, Achim Lothar) 13:30 14:00

Keynote speakers

Morris Brown, MD

Queen Mary University of London, UK



Dr. Brown is Professor of Endocrine Hypertension at the Centre for Clinical Pharmacology and Precision Medicine at Queen Mary University of London. He qualified in classics and medicine from Cambridge and trained in clinical pharmacology.

Dr. Brown's research aims to discover causes of hypertension and to optimise its management. As President of the British Hypertension Society 2005-2007 he established a research network that conducted a series of clinical trials, the 'PATHWAY' programme establishing optimal treatment for different categories of Hypertension.

His current research is mainly focussed on the adrenal gland, and the small aldosterone-producing adenomas which are a common cause of hypertension, spanning from genetics and molecular biology to invasive and non-invasive techniques for diagnosis.

Timothy A. McKinsey, PhD

University of Colorado Anschutz Medical Campus, Denver, USA



Dr. McKinsey is a Professor in the Department of Medicine at the University of Colorado Anschutz Medical Campus in Denver, where he holds the Joseph and Rose LaConte Endowed Chair in Cardiology. Dr. McKinsey is also Associate Division Head for Translational Research and Founding Director of the university's Consortium for Fibrosis Research & Translation (CFReT; www.cfret.org). He obtained a PhD in Microbiology and Immunology from Vanderbilt University School of Medicine, studying NF- κ B signaling in the laboratory of Dr. Dean Ballard. Dr. McKinsey's postdoctoral training was done in the laboratory of Dr. Eric Olson at the University of Texas Southwestern Medical Center in Dallas, where he investigated transcriptional control of muscle development and growth.

Prior to joining the faculty of the University of Colorado, Dr. McKinsey spent eight years in industry (Myogen/Gilead), where he recruited and managed a team of 18 scientists focused on small molecule drug discovery for cardiovascular/pulmonary/renal diseases. Current interests of Dr. McKinsey's lab include defining signaling and epigenetic mechanisms that control heart failure.

General Information

Venue


University of Freiburg
Institute of Experimental and Clinical Pharmacology and Toxicology
Otto-Krayer-Haus
Albertstr. 25
79104 Freiburg, Germany

Dinner reception

Haus Zur Lieben Hand
Löwenstraße 16
79098 Freiburg

Joint walk from conference venue to dinner reception through Freiburg old town (approximately 1.7 km). Please contact the registration desk in case you need assistance.

Participation requires separate registration.



Sponsors

ESAC Germany is generously supported in the organization of this conference by

- Bayer AG (10.000 EUR)
- Boehringer Ingelheim Pharma GmbH & Co. KG (10.000 EUR)

The ADMIRE Network is funded by the German Research Foundation (DFG).

Local organizer

PD Dr. Achim Lothar

Institute of Experimental and Clinical Pharmacology and Toxicology
University of Freiburg
Department II
Alberstr. 25
79104 Freiburg

Interdisciplinary Medical Intensive Care
Medical Center – University of Freiburg
Hugstetter Str. 55
79106 Freiburg

meeting@admire-network.org
<http://meeting.admire-network.org>